Johnson & Johnson reported Phase 3 results showing Tecvayli improved key outcomes when moved earlier in the multiple myeloma treatment sequence. In the MajesTEC-9 trial the dual‑targeting antibody reduced the combined risk of progression or death versus standard regimens, and a separate study reported a meaningful drop in mortality. J&J said the data support efforts to broaden Tecvayli’s label from late-line to earlier relapsed disease, and the company plans discussions with regulators. The results bolster J&J’s bid to build a dominant myeloma franchise alongside Darzalex and CAR-T assets; regulators have already engaged on priority review pathways for related submissions.